Abstract:Objectives: To explore whether asymptomatic inflammatory prostatitis is associated with prostatic enlargement beyond that of benign prostatic hyperplasia patients without asymptomatic inflammatory prostatitis, and whether asymptomatic inflammatory prostatitis affects long-term outcomes of transurethral resection of the prostate. Methods: The present study involved 106 benign prostatic hyperplasia patients who underwent transurethral resection of the prostate. Clinical and pathological parameters were compared between those with benign prostatic hyperplasia associated with asymptomatic inflammatory prostatitis and those with benign prostatic hyperplasia alone. Results: A total of 55 patients (52%) were found to have benign prostatic hyperplasia and asymptomatic inflammatory prostatitis, whereas 51 patients (48%) had benign prostatic hyperplasia alone. The prostate volume of the benign prostatic hyperplasia/asymptomatic inflammatory prostatitis group was significantly larger than the benign prostatic hyperplasia alone group: 68.1 cm(3) (interquartile range 45.7-86.3) versus 44.1 cm(3) (interquartile range 30.9-72.1), P = 0.036. In terms of histopathological analysis, benign prostatic hyperplasia/asymptomatic inflammatory prostatitis patients were more likely to show mild (53%), focal (67%) and stromal (40%) prostatic inflammation in our study. Furthermore, statistically significant differences of International Prostate Symptom Score were found 3 years after transurethral resection of the prostate, with benign prostatic hyperplasia/asymptomatic inflammatory prostatitis patients reporting higher (worse) scores than benign prostatic hyperplasia alone patients (P = 0.025). Conclusions: Chronic prostatic inflammatory process might progressively conduce to benign prostatic hyperplasia development, which can also result in prostate enlargement and worsen long-term postoperative International Prostate Symptom Scores. Multicenter studies with larger cohorts and longer follow-up periods are required to confirm these findings.

Association study of SIRT1 expression with benign prostatic hyperplasia

[Expression of Tyrosine Phosphatase Containing C-src Homology SH-2 in Benign Prostate Hyperplasia].

Expressions of Shh and Stathmin in Prostatic Diseases and Their Clinical Significances

A Retrospective Study: Correlation of Histologic Inflammation in Biopsy Specimens of Chinese Men Undergoing Surgery for Benign Prostatic Hyperplasia with Serum Prostate-Specific Antigen.

Expression of BRG1 and BRM Proteins in Prostatic Cancer

Correlation Between Molecular Biomarkers and Risk Factors for the Clinical Progression of Benign Prostatic Hyperplasia Using Tissue Micro Array Immuno Staining

Expression of Ki-67, Bcl-2, Bax and Caspase-3 in Benign Prostatic Hyperplasia Combined with Prostatitis and Their Significances

THE RELATIONSHIP OF THE PROLIFERATION AND PHENOTYPIC MODULATION OF THE STROMAL CELLS AND THE EXPRESSION OF ESTROGEN RECEPTOR α IN BENIGN PROSTATIC HYPERPLASIA

Inhibitor of DNA Binding-1 Overexpression in Prostate Cancer: Relevance to Tumor Differentiation

Analysis of the pathological characteristics after biopsy and surgery in BPH patients with abnormal serum PSA level

Expression of BRMS1 gene in prostate cancer and its clinical significance

S100A4 modulates cell proliferation, apoptosis and fibrosis in the hyperplastic prostate

Broad and Diverse Roles of Sphingosine-1-Phosphate/Sphingosine-1-Phosphate Receptors in the Prostate

Effect of Hypertension on Cell Proliferation and Apoptosis in Benign Prostatic Hyperplasia

AB200. SIRT1 Expression is Elevated in Human Prostate Cancer

Study on Expression of PTEN/MMAC1/TEP1,TGF-β1 and Their Biological Significance in Benign Prostatic Hyperplasia and Prostatic Cancer

Role of Inflammation in Benign Prostatic Hyperplasia Development among Han Chinese: A Population‐based and Single‐institutional Analysis

The Effect of Prostatitis With Benign Prostatic Hyperplasia on Serum Prostate Specific Antigen Level

[Updated Roles of SIRT1 in Prostate Diseases].

Study of cronical prostatitis and benigh prostatic hyperplasia

SIRT3 affects mitochondrial metabolic reprogramming via the AMPK–PGC‐1α axis in the development of benign prostatic hyperplasia